AI and Covid’s symbiotic relationship may make for tech’s Trojan horse
With AI more than rising to the challenge of Covid-19, its spread throughout the business ecosphere will only be a matter of time – and industries are already changing because...
Analysis
Different paths to the same destination: screening for Covid-19
Medical Device Network takes a look at the differences between PCR, LFT and antibody tests...
Lilly’s partnership with Indian drugmakers will expand access to Covid-19 treatment
The pacts will increase the availability of baricitinib in India as it battles a catastrophic second wave of coronavirus.
Covid-19 vaccine inequity: the debate over patent waivers intensifies
Severe vaccine shortages in poorer countries have brought the issue of intellectual property rights to the fore.
‘Factory-in-a-box’: bringing new scale to cell therapy manufacturing
Manufacturing challenges have been a bottleneck for cell therapies since these advanced products first came to be. Cellares co-founder and...
Baidu founder and CEO says now is the time for AI-powered SBDD drug discovery
By Elles Houweling Robin Li, CEO and founder of Chinese internet giant Baidu, says he has realised a lifelong dream by entering the field of AI-enabled structure-based drug discovery (SBDD).…
Changing the face of pharma sales with AI
Covid-19 has forced pharmaceutical salespeople out of the office and on to Zoom, a drastic change to the in-person meetings with clinicians that reps have traditionally relied on. This move,…
How is activity in the pharma sector recovering from Covid-19’s impact?
The pharma sector is now a relatively strong performer in the world economy, with sectoral activity above pre-pandemic levels in the first quarter of 2021, according to GlobalData. In Q1…
Pfizer forecasts $26bn of Covid-19 vaccine revenue after first-quarter success
As the company behind one of the world’s leading Covid-19 vaccines, it will come as no surprise that Pfizer has seen impressive financial growth in this year’s first quarter. According…
CytoReason Q&A: moving beyond animal testing in drug research
Animal testing is the first preclinical step in the development of any drug; the safety and efficacy of a treatment must be evaluated in animal models before it can move…
NICE: the five-year plan to improve patients’ access to innovative treatments
The Covid-19 pandemic and its unprecedented demands have forced health authorities the world over to reassess the way they work – and the UK’s National Institute of Health and Care…
